Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Dyslipidemia is associated with a prothrombotic phenotype; however, the mechanisms responsible for enhanced platelet reactivity remain unclear. Proatherosclerotic lipid abnormalities are associated with both enhanced oxidant stress and the generation of biologically active oxidized lipids, including potential ligands for the scavenger receptor CD36, a major platelet glycoprotein. Using multiple mouse in vivo thrombosis models, we now demonstrate that genetic deletion of Cd36 protects mice from hyperlipidemia-associated enhanced platelet reactivity and the accompanying prothrombotic phenotype. Structurally defined oxidized choline glycerophospholipids that serve as high-affinity ligands for CD36 were at markedly increased levels in the plasma of hyperlipidemic mice and in the plasma of humans with low HDL levels, were able to bind platelets via CD36 and, at pathophysiological levels, promoted platelet activation via CD36. Thus, interactions of platelet CD36 with specific endogenous oxidized lipids play a crucial role in the well-known clinical associations between dyslipidemia, oxidant stress and a prothrombotic phenotype.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Platelet hyperreactivity and thrombosis risk are enhanced in the setting of numerous conditions associated with atherosclerotic heart disease, such as hyperlipidemia, oxidant stress, and hyperglycemia (Podrez et al., 2007; Chen et al., 2008; Zhu et al., 2012a).”
From Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk (2016) · cites this paper as Podrez et al., 2007
Citations
Cites
Antiinflammatory Properties of HDL
Barter, P. J., Nicholls, S., Rye, K.-A., Anantharamaiah, G. M., Navab, M., & Fogelman, A. M. (2004) · Circulation Research · doi:10.1161/01.res.0000146094.59640.13 · Cited by 1,394 · cited 1×
“Because anti-inflammatory and antioxidant effects of HDL are well documente”
BackgroundFebbraio, M., Hajjar, D. P., & Silverstein, R. L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci14006 · Cited by 1,193 · cited 1×
“CD36 is implicated in a variety of pathological conditions, including atherosclerosis, diabetes and innate immunit”
BackgroundSelf-citationFebbraio, M., Podrez, E. A., Smith, J. D., Hajjar, D. P., Hazen, S. L., Hoff, H. F., Sharma, K., & Silverstein, R. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9259 · Cited by 1,044 · cited 1×
“Absence of CD36 in a mouse model of atherogenesis results in significant inhibition of atherosclerosi”
BackgroundSelf-citationCirculating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E
Huo, Y., Schober, A., Forlow, S. B., Smith, D. F., Hyman, M. C., Jung, S., Littman, D. R., Weber, C., & Ley, K. (2003) · Nature Medicine · doi:10.1038/nm810 · Cited by 1,005 · cited 1×
“Platelet P-selectin mediates the formation of platelet-monocyte aggregates, which have been implicated in several vascular disease processe”
BackgroundCD36 is a sensor of diacylglycerides
Hoebe, K., Georgel, P., Rutschmann, S., Du, X., Mudd, S., Crozat, K., Sovath, S., Shamel, L., Hartung, T., Zähringer, U., et al. (2005) · Nature · doi:10.1038/nature03253 · Cited by 873 · cited 1×
“To address any potential issues related to the mixed genetic background of the Cd36 −/− and Apoe −/− Cd36 −/− mice, we used independently generated, CD36-deficient 'oblivious' mic”
MethodWatson, A. D., Leitinger, N., Navab, M., Faull, K. F., Hörkkö, S., Witztum, J. L., Palinski, W., Schwenke, D., Salomon, R. G., Sha, W., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.21.13597 · Cited by 753
Self-citationCD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanism
André, P., Prasad, K. S. S., Denis, C. V., He, M., Papalia, J. M., Hynes, R. O., Phillips, D. R., & Wagner, D. D. (2002) · Nature Medicine · doi:10.1038/nm0302-247 · Cited by 726
Platelet Function in Hyperlipoproteinemia
Carvalho, A. C. A., Colman, R. W., & Lees, R. S. (1974) · New England Journal of Medicine · doi:10.1056/nejm197402212900805 · Cited by 679
Platelet Hyperreactivity and Prognosis in Survivors of Myocardial Infarction
Trip, M. D., Cats, V. M., van Capelle, F. J. L., & Vreeken, J. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005313222201 · Cited by 617
Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro
Podrez, E. A., Schmitt, D., Hoff, H. F., & Hazen, S. L. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5549 · Cited by 492
Self-citation
Cited by
Items 201–300 of 513
Robles, A. P., Cate, H. T., Schulz, A., Prochaska, J. H., Rapp, S., Koeck, T., Panova‐Noeva, M., Heitmeier, S., Schwers, S., Leineweber, K., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-13174-5 · Cited by 42
Zimman, A., Titz, B., Komisopoulou, E., Biswas, S., Graeber, T. G., & Podrez, E. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084488 · Cited by 38
“increased in plasma of hyperlipidemic mice and in plasma of subjects with low HDL level, and promote platelet activation and hyper-reactivity [3].”
BackgroundMethodInfluentialSelf-citationOur Expanding View of Platelet Functions and Its Clinical Implications
Ombrello, C., Block, R., & Morrell, C. N. (2010) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-010-9213-7 · Cited by 38
“This knowledge helps to identify two new potential targets for anti-platelet drug development in the prevention and treatment of atherosclerosis; CD36 and MAPK members.”
BackgroundInfluentialCysteine sulfenylation by CD36 signaling promotes arterial thrombosis in dyslipidemia
Yang, M., Li, W., Harberg, C. A., Chen, W., Yue, H., Ferreira, R. B., Wynia‐Smith, S. L., Carroll, K. S., Zielonka, J., Flaumenhaft, R. C., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001609 · Cited by 40
“Oxidized lipids in low-density lipoproteins (oxLDL) are a risk factor for athero-thrombosis and are recognized by platelet scavenger receptor CD36. oxLDL binding to CD36 promotes platelet activation and thrombosis by promoting generation of reactive oxygen species.”
BackgroundSelf-citationBarrachina, M. N., Pernes, G., Becker, I. C., Allaeys, I., Hirsch, T. I., Groeneveld, D. J., Khan, A. O., Freire, D., Guo, K., Carminita, E., et al. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00305-y · Cited by 44
Type 2 scavenger receptor CD36 in platelet activation: the role of hyperlipemia and oxidative stress
Silverstein, R. L. (2009) · Clinical Lipidology · doi:10.2217/clp.09.57 · Cited by 46
Self-citationYa, F., Li, K., Chen, H., Tian, Z., Fan, D., Shi, Y., Song, F., Xu, X., Ling, W., Adili, R., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1722621 · Cited by 39
Regulation of Platelet Function by Class B Scavenger Receptors in Hyperlipidemia
Zimman, A., & Podrez, E. A. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.207498 · Cited by 39
Self-citationYu, P., Xiong, T., Tenedero, C. B., Lebeau, P. F., Ni, R., MacDonald, M. E., Gross, P. L., Austin, R. C., & Trigatti, B. L. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.305140 · Cited by 39
Berger, M., Raslan, Z., Aburima, A. A., Magwenzi, S., Wraith, K. S., Spurgeon, B. E. J., Hindle, M. S., Law, R., Febbraio, M., & Naseem, K. M. (2019) · Haematologica · doi:10.3324/haematol.2018.213348 · Cited by 35
“CD36 is required for oxidized low-density lipoprotein modulation of cyclic adenosine monophosphate signaling Previously, we and others have shown that CD36 transduces the effects of oxLDL into platelet hyperactivity.(14,18,28,29) To examine the role of CD36 in linking oxLDL to altered cAMP signaling, we used a three-p…”
MethodSelf-citationA Protective Role for CD154 in Hepatic Steatosis in Mice
Villeneuve, J., Lepreux, S., Mulot, A., Bérard, A. M., Higa-Nishiyama, A., Costet, P., de Lédinghen, V., Bioulac‐Sage, P., Balabaud, C. P., Nurden, A. T., et al. (2010) · Hepatology · doi:10.1002/hep.23935 · Cited by 39
“Hyperlipidemia has been previously associated with platelet activation and release of sCD154.(51,52) We monitored platelet activation and CD154 expression, both on platelets and in a circulating soluble form, in mice subjected to an olive oil–rich diet or to TM treatment.”
BackgroundThe clot thickens—oxidized lipids and thrombosis
Jackson, S. P., & Calkin, A. C. (2007) · Nature Medicine · doi:10.1038/nm0907-1015 · Cited by 35
Alemany, M. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.03.003 · Cited by 40
“Platelet function is altered by hyperlipidemia [210,211] and”
BackgroundYang, M., Chiu, J., Scartelli, C., Ponzar, N. L., Patel, S., Patel, A., Ferreira, R. B., Keyes, R. F., Carroll, K. S., Pozzi, N., et al. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.03.034 · Cited by 35
Birukova, A. A., Lee, S., Starosta, V., Wu, T., Ho, T. F., Kim, J., Berliner, J. A., & Birukov, K. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030957 · Cited by 34
“Determination of the in vivo concentrations of OxPL under physiologic and pathologic conditions remains an open issue. Published measurements differ significantly and often represent different OxPL species measured in different body compartments. In two reports, combined concentration of all oxidized phospholipids in…”
InfluentialYa, F., Xu, X., Shi, Y., Gallant, R. C., Song, F., Zuo, X., Zhao, Y., Tian, Z., Zhang, C., Xu, X., et al. (2019) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900662 · Cited by 34
Duan, H., Song, P., Li, R., Su, H., & He, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1161657 · Cited by 40
“In addition, the expression of P-selectin and activity of integrin αIIbβ3 are increased through interaction between ox-LDL and CD36 in resting platelets, and then the expression of LOX-1 is increased (Podrez et al., 2007).”
BackgroundLiu, R., He, Y., Li, B., Liu, J., Ren, Y., Han, W., Wang, X., & Zhang, L. (2012) · Molecules and Cells · doi:10.1007/s10059-012-0054-x · Cited by 33
Bain, W., Olonisakin, T. F., Yu, M., Qu, Y., Hulver, M., Xiong, Z., Li, H., Pilewski, J. M., Mallampalli, R. K., Nouraie, M. S., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018026286 · Cited by 31
Self-citationFeldman, C. H., & Anderson, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577303 · Cited by 34
“These include: (i) inhibition of the formation of oxLDL-C, which triggers platelet activation via interaction with the scavenger receptors, LOX-1 and CD36, both of which are expressed on platelets (174, 175); (ii) inhibition of PLA2, resulting in decreased release of TxA2 (176); (iii) decreased expression of the adhes…”
BackgroundThe role of oxidized phospholipids in the development of disease
Nie, J. S., Yang, J., Wei, Y., & Wei, X. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100909 · Cited by 33
Pathophysiology of the proatherothrombotic state in the metabolic syndrome
Navarro, H. G. (2009) · Frontiers in Bioscience-Scholar · doi:10.2741/s57 · Cited by 36
“Podrez et al (120) demonstrated that the interaction of platelet CD36, a major platelet glycoprotein, with specific endogenous oxidized lipids promotes platelet activation and thrombosis.”
BackgroundReceptor-Mediated Mechanism Controlling Tissue Levels of Bioactive Lipid Oxidation Products
Kim, Y.-W., Yakubenko, V. P., West, X. Z., Gugiu, G. B., Renganathan, K., Biswas, S., Gao, D., Crabb, J. W., Salomon, R. G., Podrez, E. A., et al. (2015) · Circulation Research · doi:10.1161/circresaha.117.305925 · Cited by 31
Self-citationPlatelet lipid metabolism in vascular thrombo-inflammation
Manke, M.-C., Ahrends, R., & Borst, O. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108258 · Cited by 34
Springstead, J. R., Gugiu, B. G., Lee, S., Cha, S., Watson, A. D., & Berliner, J. A. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m025320 · Cited by 30
Overcoming β-Cell Dysfunction in Type 2 Diabetes Mellitus: CD36 Inhibition and Antioxidant System
Park, I. R., Chung, Y. G., & Won, K. C. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0796 · Cited by 38
“CD36 is a multifunctional glycoprotein central to both physiological and pathological events, such as fatty acid metabolism, glucose regulation, inflammation, and cellular signaling [35-37].”
Masuda, Y., Tamura, S., Matsuno, K., Nagasawa, A., Hayasaka, K., Shimizu, C., & Moriyama, T. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.03.002 · Cited by 29
“In platelets, oxLDL induces or enhances platelet activation in a CD36-dependent manner, and this is associated with the prothrombotic phenotype in patients with dyslipidemia [28–31].”
BackgroundTreatment of dyslipidemia in kidney transplantation
Ponticelli, C. E., Arnaboldi, L., Moroni, G. L., & Corsini, A. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1732921 · Cited by 34
L-4F Alters Hyperlipidemic (But Not Healthy) Mouse Plasma to Reduce Platelet Aggregation
Buga, G. M., Navab, M., Imaizumi, S., Reddy, S. T., Yekta, B., Hough, G., Chanslor, S., Anantharamaiah, G. M., & Fogelman, A. M. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.200162 · Cited by 29
Platelet lipidome: Dismantling the “Trojan horse” in the bloodstream
Chatterjee, M. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14721 · Cited by 30
Platelet hyperreactivity, scavenger receptors and atherothrombosis
Valiyaveettil, M., & Podrez, E. A. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03422.x · Cited by 29
Self-citationFAT/CD36 Participation in Human Skeletal Muscle Lipid Metabolism: A Systematic Review
Ramos‐Jiménez, A., Zavala-Lira, R. A., Moreno-Brito, V., & González-Rodríguez, E. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010318 · Cited by 34
“Furthermore, oxidative stress and a prothrombotic phenotype perturb FAT/CD36 function and induce metabolic diseases as obesity, insulin resistance, diabetes, atherothrombotic disease, chronic kidney disease, neurodegenerative disorders and multiple sclerosis [67,68].”
BackgroundPCSK9 as an Atherothrombotic Risk Factor
Sotler, T., & Šebeštjen, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031966 · Cited by 32
“PCSK9-induced platelet activation involves these two receptors on a platelet’s surface [48,49].”
BackgroundUpdate on pathological platelet activation in coronary thrombosis
Elia, E., Montecucco, F., Portincasa, P., Sahebkar, A., Mollazadeh, H., & Carbone, F. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27575 · Cited by 29
“While genetic deletion of CD36 significantly attenuates PLT reactivity and thrombosis susceptibility in experimental models (Podrez et al., 2007), oxLDL‐treated PLTs, inhibit endothelial regeneration (Daub et al., 2010), and enhance both transendothelial monocyte migration and foam cell‐ formation…”
BackgroundThe Role of CD36/GPIV in Platelet Biology
Bendas, G., & Schlesinger, M. (2023) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0043-1768935 · Cited by 34
“70 In line with earlier studies, they demonstrated that speci fi c oxidized glycerophospholipids (oxPLs) generated during oxidative stress represent high-af fi nity ligands for CD36.”
BackgroundResultAssinger, A., Koller, F., Schmid, W., Zellner, M., Koller, E., & Volf, I. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.07.018 · Cited by 27
What Do Experimental Models Teach Us About Comorbidities in Stroke?
Cho, S., & Yang, J. (2018) · Stroke · doi:10.1161/strokeaha.117.017793 · Cited by 28
Koskinas, K. C., Windecker, S., Buhayer, A., Gencer, B., Pedrazzini, G., Mueller, C., Cook, S., Muller, O., Matter, C. M., Räber, L., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.23112 · Cited by 26
“High levels of LDL-C (particularly oxidized LDL) correlate with plasma fibrinogen levels and platelet activation.(38) Statins inhibit platelet aggregation, reduce platelet-mediated thrombus formation,(39) augment the pharmacodynamic response to antiplatelet agents, and attenuate platelet reactivity in patients undergo…”
BackgroundMaaninka, K., Neuvonen, M., Kerkelä, E., Hyvärinen, K., Palviainen, M., Kamali‐Moghaddam, M., Federico, A., Greco, D., Laitinen, S., Öörni, K., et al. (2023) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2023.151311 · Cited by 34
Platelet mitochondria: the mighty few
Ajanel, A., Campbell, R. A., & Denorme, F. (2023) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000772 · Cited by 31
“Yang M, Silverstein RL. CD36 and ERK5 link dyslipidemia to apoptotic-like platelet procoagulant function.”
BackgroundInfluentialLipid Metabolism and Signaling in Platelet Function
Paes, A. M. D. A., Gaspar, R. S., Eduardo Fuentes, Q., Wehinger, S., Palomo, I. F., & Trostchansky, A. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-11488-6_7 · Cited by 28
Pasterk, L., Lemesch, S., Leber, B., Trieb, M., Ćurčić, S., Stadlbauer, V., Schuligoi, R., Schicho, R., Heinemann, Á., & Marsche, G. (2016) · Scientific Reports · doi:10.1038/srep22104 · Cited by 26
Oxidised Low-Density Lipoprotein-Induced Platelet Hyperactivity—Receptors and Signalling Mechanisms
Berger, M., & Naseem, K. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169199 · Cited by 31
“In vitro OxPCCD36 induces increased platelet P-selectin expression OxPCCD36 Human Washed platelets [61]”
BackgroundInfluentialMa, M., Hou, C. J., & Liu, J. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1148486 · Cited by 26
Sources of tissue factor that contribute to thrombosis after rupture of an atherosclerotic plaque
Owens, A. P., & Mackman, N. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.02.026 · Cited by 25
Yi, X., Wang, C., Zhou, Q., & Lin, J. (2017) · BMC Neurology · doi:10.1186/s12883-016-0788-8 · Cited by 25
“Chronic hyperlipidemia plays a key role in platelet activation both in vivo [31] and in vitro [32].”
Backgroundvan Geffen, J. P., Swieringa, F., van Kuijk, K., Tullemans, B. M. E., Solari, F. A., Peng, B., Clemetson, K. J., Farndale, R. W., Dubois, L. J., Sickmann, A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-78522-9 · Cited by 26
A contemporary viewpoint on ‘aspirin resistance’
Kuzniatsova, N., Shantsila, E., Blann, A. D., & Lip, G. Y. H. (2012) · Annals of Medicine · doi:10.3109/07853890.2011.605388 · Cited by 25
Lipids and Antiplatelet Therapy: Important Considerations and Future Perspectives
Đukanović, N., Obradovic, S. D., Zdravkovic, M. D., Đurašević, S., Stojković, M., Tosti, T. B., Jasnic, N. I., Đorđević, J., & Todorović, Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063180 · Cited by 28
“Receptor classes SR-BI and CD36 have the largest role in lipid/lipoprotein metabolism [63].”
BackgroundInfluentialPleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis
Puccini, M., Landmesser, U., & Rauch, U. (2022) · Metabolites · doi:10.3390/metabo12030226 · Cited by 27
“PCSK9 exerts its effects on platelet activation by binding to the scavenger receptor CD36 [43] and, therefore, activating CD36-dependent signalling pathways [61] (Figure 2).”
BackgroundPlatelet Redox Imbalance in Hypercholesterolemia: A Big Problem for a Small Cell
Morotti, A., Barale, C., Melchionda, E., & Russo, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911446 · Cited by 26
“Platelets from individuals affected by CAD and/or familial hypercholesterolemia show increased reactivity when activated by classic platelet agonists.”
BackgroundInfluentialCysteine and methionine oxidation in thrombotic disorders
Yang, M., & Smith, B. C. (2023) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2023.102350 · Cited by 26
Nardin, M., Verdoia, M., Cao, D., Nardin, S., Kedhi, E., Galasso, G., Hof, A. W. J. V. ’., Condorelli, G., & Luca, G. D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12186074 · Cited by 27
“The increased smoking-induced lipid oxidation products bind platelet scavenger receptor CD36, which in turn results in increased platelet aggregation response [124].”
NADPH-oxidases as potential pharmacological targets for thrombosis and depression comorbidity
Amadio, P., Sandrini, L., Zarà, M., Barbieri, S. S., & Ieraci, A. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103060 · Cited by 28
“In particular, the signal mediated by CD40 is mainly involved in atherosclerotic processes [152], while the signals mediated by collagen/GPVI and oxLDL/CD36 are preferentially associated with thrombotic and thromboembolic processes [63,64].”
BackgroundStübiger, G., Wuczkowski, M., Bicker, W., & Belgacem, O. (2014) · Analytical Chemistry · doi:10.1021/ac500719u · Cited by 24
Xu, X., Chen, D., Ye, X., Xia, W., Xu, Y., Chen, Y., Shao, Y., Deng, J., Ding, H., Liu, J., et al. (2021) · Blood · doi:10.1182/blood.2021011131 · Cited by 23
Endothelial Cell CD36 Reduces Atherosclerosis and Controls Systemic Metabolism
Rekhi, U., Omar, M. A., Alexiou, M. V., Delyea, C., Immaraj, L., Elahi, S., & Febbraio, M. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.768481 · Cited by 30
Self-citationSalomon, R. G., & Gu, X. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200207z · Cited by 23
Self-citationYang, S., Li, Y., & Du, D. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.10.003 · Cited by 23
“Because ox-LDL is present in the circulation [17,18], it can make contact with platelets.”
BackgroundAspirin resistance in patients with type II diabetes mellitus
Taşdemir, E., Toptaş, T., Demır, C., Esen, R., & Atmaca, M. (2013) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2013.861549 · Cited by 25
“The role of hyperlipidemia on aspirin resistance was demonstrated by in-vivo and in-vitro studies (24,25).”
BackgroundPlatelet reactivity in dyslipidemia: atherothrombotic signaling and therapeutic implications
Yang, M., & Kholmukhamedov, A. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm.2021.01.256 · Cited by 24
“vated by classic platelet agonists [7, 9, 10].”
BackgroundInfluentialCombination of Colchicine and Ticagrelor Inhibits Carrageenan‐Induced Thrombi in Mice
Zhang, B., Huang, R. Y., Yang, D., Chen, G., Chen, Y., Han, J., Zhang, S., Ma, L., & Yang, X. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/3087198 · Cited by 27
“It has been found that dyslipidemia enhanced thrombosis can be corrected in CD36 de fi ciency mice [32].”
Impact of Physical Exercise on Platelets: Focus on Its Effects in Metabolic Chronic Diseases
Barale, C., Melchionda, E., Tempesta, G., Morotti, A., & Russo, I. (2023) · Antioxidants · doi:10.3390/antiox12081609 · Cited by 27
“Oxidized lipoproteins are deeply involved in many biochemical events leading to atherosclerosis processes as well as platelet hyperactivation [196,197].”
BackgroundCharacterization of covalent modifications of HDL apoproteins by endogenous oxidized phospholipids
Gao, D., & Podrez, E. A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.11.012 · Cited by 25
Self-citationNagy, M., van Geffen, J. P., Stegner, D., Adams, D. J., Braun, A., Witt, S., Elvers, M., Geer, M. J., Kuijpers, M. J. E., Kunzelmann, K., et al. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00099 · Cited by 22
Redox Mechanisms of Platelet Activation in Aging
Gu, S. X., & Dayal, S. (2022) · Antioxidants · doi:10.3390/antiox11050995 · Cited by 25
Zheng, T. J., Kohs, T. C. L., Mueller, P. A., Pang, J., Reitsma, S. E., Parra‐Izquierdo, I., Melrose, A. R., Yang, L., Choi, J., Zientek, K. D., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007169 · Cited by 31
Dragani, A., Falco, A., Santilli, F., Basili, S., Rolandi, G., Cerasa, L., Lattanzio, S., Ciabattoni, G., Patrono, C., & Davì, G. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-12-0899 · Cited by 23
“Moreover, the link between lipid peroxidation and platelet activation is likely to be far more complex than explored in the present investigation, involving more products of lipid peroxidation than 8-iso-PGF2α and other iso-eicosanoids: indeed, phosphatidylcholine oxidised and truncated at the sn2 position (oxPCCD36)…”
BackgroundPlatelet apoptosis and agonist-mediated activation in myelodysplastic syndromes
Jiménez‐Yuste, V., Fernandez-Bello, I., Arias‐Salgado, E. G., Álvarez, M., Martín, M., de Paz, R., & Butta, N. V. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-09-0670 · Cited by 20
Berger, M., Wraith, K. S., Woodward, C., Aburima, A. A., Raslan, Z., Hindle, M. S., Moellmann, J., Febbraio, M., & Naseem, K. M. (2018) · Platelets · doi:10.1080/09537104.2018.1466386 · Cited by 21
Self-citationAntiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
Pęczek, P., Leśniewski, M., Mazurek, T., Szarpak, Ł., Filipiak, K. J., & Gąsecka, A. (2021) · Life · doi:10.3390/life11060466 · Cited by 23
“Previous studies have shown that the interaction of CD36 with ox-LDL triggers signaling pathways that activate platelets, inducing the expression of P-selectin and the activation of integrin αIIbβ3 (the receptor for fibrinogen), therefore facilitating the formation of platelet–leukocyte complexes via P-selectin and th…”
BackgroundUeno, M., Nakagawa, T., Nagai, Y., Nishi, N., Kusaka, T., Kanenishi, K., Onodera, M., Hosomi, N., Huang, C., Yokomise, H., et al. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2011.01172.x · Cited by 24
Elucidation of lipoprotein particles structure by proteomic analysis
Alonzi, T., Mancone, C., Amicone, L., & Tripodi, M. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.1.91 · Cited by 21
Targeting Activated Platelets and Fibrinolysis
Adili, R., Xu, X., Reddy, E. C., & Ni, H. (2014) · Circulation Research · doi:10.1161/circresaha.114.303600 · Cited by 21
“conditions, circulating platelets may be partially activated or in a hyperactive state.(31) Therefore, scFv SCE5 -scuPA may bind”
BackgroundOxidized phospholipid damage signals as modulators of immunity
Choi, J. H., & Kagan, J. C. (2025) · Open Biology · doi:10.1098/rsob.240391 · Cited by 24
“Additionally, CD36 engagement with oxidized phospholipids can trigger signalling pathways that induce oxidative stress responses, including the upregulation of NADPH oxidase activity and the production of ROS, thus perpetuating inflammation and oxidative damage [63,70,71].”
Factors affecting impairment of blood rheology in obese subjects
Hitsumoto, T. (2012) · Journal of Cardiology · doi:10.1016/j.jjcc.2012.06.012 · Cited by 20
The Role of Snake Venom Disintegrins in Angiogenesis
Clissa, P. B., Della-Casa, M. S., Zychar, B. C., & Sanabani, S. S. (2024) · Toxins · doi:10.3390/toxins16030127 · Cited by 20
Nardin, M., Verdoia, M., Negro, F., Rolla, R., Tonon, F., & Luca, G. D. (2019) · European Journal of Clinical Investigation · doi:10.1111/eci.13181 · Cited by 21
Fat(al) attraction: Oxidized lipids act as “eat‐me” signals
Fadeel, B., Quinn, P. J., Xue, D., & Kagan, V. E. (2007) · HFSP journal · doi:10.2976/1.2800110 · Cited by 23
Hyperlipidemia, Disease Associations, and Top 10 Potential Drug Targets: A Network View
Rai, S., & Bhatnagar, S. (2016) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2015.0172 · Cited by 20
“A role for the major secreted platelet glycoprotein CD36 in activation of platelets due to oxidized lipids has also been established (Podrez et al., 2007).”
Cross-Talk between Lipoproteins and Inflammation: The Role of Microvesicles
Chiva‐Blanch, G., & Badimón, L. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122059 · Cited by 20
Nkambule, B. B., Davison, G. M., & Ipp, H. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.01.031 · Cited by 22
The platelet “sugar high” in diabetes
Ni, H. (2012) · Blood · doi:10.1182/blood-2012-04-420794 · Cited by 19
Oxidation-specific epitopes are major targets of innate immunity in atherothrombosis
Gritti, B. B., & Binder, C. J. (2015) · Hämostaseologie · doi:10.5482/hamo-14-11-0069 · Cited by 19
“To observe such differences, mice needed to be in a hyperlipidemic state, as no effect was observed when platelet activity in ApoE-/- and ApoE-/-CD36-/- mice on chow diet were compared (41).”
Fuentes, E., Palomo, I. F., & Rojas, A. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.11.005 · Cited by 21
“Platelet GPIV mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice [80–84].”
BackgroundWang, W., Oh, S., Koester, M., Abramowicz, S., Wang, N., Tall, A. R., & Welch, C. L. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.115.001294 · Cited by 18
“uptake of oxidized lipoproteins via platelet surface scavenger receptors.(40,41) We observed increased markers of platelet Figure 3.”
BackgroundCinnamon inhibits platelet function and improves cardiovascular system
Mehrpouri, M., Hamidpour, R., & Hamidpour, M. (2020) · Journal of Medicinal Plants · doi:10.29252/jmp.1.73.1 · Cited by 23
“73 .1 ] Journal of Medicinal Plants 5 March 2020, Vol. 19, No. 73: 1-11 reducing the expression of CD11b, CD36 and SRA [72], so indirectly reduces foam cells formation and ultimately limits the formation of atherosclerotic plaque.”
BackgroundPankratz, N., Wei, P., Brody, J. A., Chen, M., de Vries, P. S., Huffman, J. E., Nalehua, M. R., Auer, P. L., Boerwinkle, E., Cushman, M., et al. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac100 · Cited by 18
CD36‐fibrin interaction propagates FXI‐dependent thrombin generation of human platelets
Döhrmann, M., Makhoul, S., Groß, K., Krause, M., Pillitteri, D., von Auer, C., Walter, U., Lutz, J., Volf, I., Kehrel, B. E., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201903189r · Cited by 18
Zhang, Y., Jiang, F., Chen, Y., & Ju, L. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.779753 · Cited by 17
“Diabetes, obesity and other metabolic syndromes are well known to be associated with platelet hyperactive functions and exhibit prothrombotic phenotypes (Podrez et al., 2007; Santilli et al., 2012; Ju et al., 2018).”
BackgroundYa, F., Xu, X., Tian, Z., Gallant, R. C., Song, F., Shi, Y., Wu, Y., Wan, J., Zhao, Y., Adili, R., et al. (2019) · Food & Function · doi:10.1039/c9fo01686d · Cited by 17
Gautam, I., Storad, Z. A., Filipiak, L., Huss, C., Meikle, C. K., Worth, R. G., & Wuescher, L. M. (2020) · Biology · doi:10.3390/biology9100343 · Cited by 17
Microvesicles in plasma reflect coronary flow reserve in patients with cardiovascular disease
Bryl‐Górecka, P., James, K., Törngren, K., Haraldsson, I., Gan, L., Svedlund, S., Olde, B., Laurell, T., Ömerovic, E., & Erlinge, D. (2021) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00869.2020 · Cited by 17
Petta, S., Handberg, A., Marchesini, G., Cammà, C., Marco, V. D., Cabibi, D., Macaluso, F. S., & Craxì, A. (2012) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2012.01641.x · Cited by 17
An Epoxyisoprostane Is a Major Regulator of Endothelial Cell Function
Zhong, W., Springstead, J. R., Al-Mubarak, R., Lee, S., Li, R., Emert, B. L., Berliner, J. A., & Jung, M. E. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400959q · Cited by 18
Cserti-Gazdewich, C. M., Dzik, S., Dorn, M. E., Quagliaroli, R. O., Xu, S., Ssewanyana, I., Nayyar, R., & Preffer, F. I. (2008) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.20443 · Cited by 17
CD36 genotype associated with ischemic stroke in Chinese Han.
Zhang, Y., Zang, J., Wang, B., Li, B., Yao, X., Zhao, H., & Li, W. (2015) · PubMed · Cited by 18
Morii, T., Ohno, Y., Kato, N., Hirose, H., Kawabe, H., Hirao, K., Eguchi, T., Maruyama, T., Hayashi, M., Saito, I., et al. (2009) · Biomarkers · doi:10.1080/13547500902811274 · Cited by 17
“CD36 (or fatty acid translocase) is a transmembrane glycoprotein of the class B scavenger receptor family, which is expressed on macrophages, platelets, microvascular endothelium, adipocytes, skeletal muscle and smooth muscle cells (Greenwalt et al. 1992, Koonen et al. 2007, Podrez et al. 2007).”
BackgroundBrennan, M., Reddy, A., Tang, W. H. W., Wu, Y., Brennan, D. M., Hsu, A., Mann, S. A., Hammer, P. L., & Hazen, S. L. (2010) · Circulation · doi:10.1161/circulationaha.109.881581 · Cited by 16
Self-citationMadan, N., Ghazi, A. R., Kong, X., Chen, E. S., Shaw, C. A., & Edelstein, L. C. (2019) · PLoS Genetics · doi:10.1371/journal.pgen.1008287 · Cited by 17
Metadata
- Authors
- Podrez, E. A., Byzova, T. V., Febbraio, M., Salomon, R. G., Ma, Y., Valiyaveettil, M., Poliakov, E., Sun, M., Finton, P. J., Curtis, B. R., Chen, J., Zhang, R., Silverstein, R. L., & Hazen, S. L.
- Affiliations
- Cleveland Clinic (US)
- Case Western Reserve University (US)
- Versiti Blood Center of Wisconsin (US)
- Corresponding author
- Podrez, Eugene A
- ORCID
- Venue
- Nature Medicine
- Published
- 2007-08-26
- Volume
- 13
- Issue
- 9
- Pages
- 1086-1095
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC3042888
- OpenAlex
- W2029684068
- Cited by
- 513
- References
- 47
- Citations by year
- 2026: 25 · 2025: 24 · 2024: 18 · 2023: 29 · 2022: 32 · 2021: 27 · 2020: 27 · 2019: 25 · 2018: 23 · 2017: 24 · 2016: 16 · 2015: 27 · 2014: 26 · 2013: 28 · 2012: 36
- FWCI
- 19.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (HL071625., P01HL046403, HL053315, HL 073311, HL076491, HL-072942, R01HL070083, P50 HL-81011, HL077107, HL077213, P01HL072942, P50HL077107, P01HL077107, R01HL077213, P01HL076491, HL 70621, HL70083, R01HL053315, HL-46403, P01HL073311, R01HL070621, P50HL081011, R01HL071625)
- National Center for Research Resources (M01RR018390)
- Topics
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- hyperlipidemia, oxidative stress, prothrombotic phenotype, oxidized lipids, platelet activation, scavenger receptors, dyslipidemia, thrombosis, HDL cholesterol
- MeSH terms
- Animals, Blood Platelets, Humans, Hyperlipidemias, Male, Phenotype, Phospholipids, Prothrombin, Thrombosis, Platelet Activation, Antigens, CD, Gene Deletion, Mice, Knockout, Oxidative Stress, CD36 Antigens, Dyslipidemias, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.